Altimmune, Inc.
Altimmune, Inc. (ALT) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAltimmune, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 105.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +105.00% |
| 2024-12-31 | $0.00B | -$0.00B | -95.31% |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $-0.00B | -$0.00B | -101.54% |
| 2021-12-31 | $0.00B | -$0.00B | -46.12% |
| 2020-12-31 | $0.01B | +$0.00B | +41.09% |
| 2019-12-31 | $0.01B | -$0.00B | -43.85% |
| 2018-12-31 | $0.01B | +$0.01B | +24792.58% |
| 2017-12-31 | $0.00B | -$0.01B | -99.21% |
| 2016-12-31 | $0.01B | -$0.01B | -50.85% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Altimmune, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Altimmune, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Altimmune, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALT revenue · 4 questionsALT's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 105.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Altimmune, Inc. SEC filings · GAAP · Altimmune, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026